However, the VASCEPA-COVID-19 trial (Table 2) has been completed, and the published results provide evidence that oral administration of icosapent ethyl for 14 days in a modest (100) sample of outpatients with COVID-19 induced an early anti-inflammatory response (consisting in the significant reduction of high-sensitivity C-reactive protein-CRP) and an improvement of symptoms (assessed by using the InFLUenza Patient-Reported Outcome score) [40]. The gene discussed is CRP; the disease is COVID-19.